Spots Global Cancer Trial Database for A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Official Title: Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
Study ID: NCT03573960
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
All India Institute of Medical Sciences, New Delhi, Delhi, India
Indraprastha Apollo Hospital, New Delhi, Delhi, India
Shetty's Hospital, Bangalore, Karnataka, India
Regional Cancer Centre, RCC, Thiruvananthapuram, Thiruvananthapuram, Kerala, India
Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
All India Institute of Medical Sciences, Bhubaneshwar, Odisa, India
S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, India
Tata Memorial Hospital, Mumbai, , India
BL Kapoor Hospital, New Delhi, New Delhi, , India
Indrayani Hospital, Alandi, Pune, , India
City Cancer Centre, Vijayawada, , India
Contact Details
Name: Medical Director
Affiliation: Eisai Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
